

a cationic lipid which is

3. 3-beta-[N-(N',N'-dimethylaminoethane)carbamoyl]cholesterol(DC-chol) or a salt of the latter.

7. (Amended) Composition according to Claim 1 [one of Claims 1 to 6], in which the immunogenic agent derived from Helicobacter is selected from a preparation of inactivated Helicobacter bacteria, a Helicobacter cell lysate, a peptide and a polypeptide from Helicobacter in purified form.

NE
9. (Amended) Composition according to Claim 1 [one of Claims 1 to 8], in which the immunogenic agent is derived from Helicobacter pylori.

14. (Amended) Use according to Claim 10 [or 13], in which the compound is 3-beta-[N-(N',N'-dimethylaminoethane)-carbamoyl]cholesterol (DC-chol) or a salt of the latter.

16. (Amended) Use according to Claim 10 [one of Claims 10 to 15], in which the Th1 type immune response is measured in mice and is characterized by a ratio of the ELISA IgG2a : IgG1 titres greater than or equal to 1 : of the ELISA IgG2a : IgG1 titres greater than or equal to 1 : 20; the IgG2a and IgG1 being immunoglobulins induced

against Helicobacter.

19. (Amended) Use according to Claim 10 [one of Claims 10 to 18], in which the immunogenic agent derived from Helicobacter is selected from a preparation of inactivated Helicobacter bacteria, a Helicobacter cell lysate, a peptide and a polypeptide from Helicobacter in purified form.

N.E
21. (Amended) Use according to Claim 10 [one of Claims 10 to 20], in which the immunogenic agent is derived from Helicobacter pylori.

22. (Amended) Use according to Claim 10 (one of Claims 10 to 21), in which the pharmaceutical composition is intended to be administered by the systemic route.

24. (Amended) Use according to Claim 22 [or 23], in which the pharmaceutical composition is intended to be administered by the systemic route in the part of a mammal, in particular of a primate, situated under its diaphragm.

25. (Amended) Use according to Claim 22 (one of Claims 22 to 24), in which the pharmaceutical composition is intended to be administered by a systemic route in the dorsolumbar region of a mammal, in particular a primate.

26. (Amended) Use according to Claim 22 (one of Claims 22 to 25), in which the pharmaceutical composition is intended to be administered by a systemic route selected from the subcutaneous route, the intramuscular route and the intradermal route.

27. (Amended) Use according to Claim 10 [one of Claims 10 to 26], in which the pharmaceutical composition is intended to be administered twice or three times by the systemic route during the same treatment, to prevent or treat a Helicobacter infection.

N.E.
CO. 22E 11 10
CONCLUSION

Although no charges are believed to be due, if there are any charges or any credits, please apply them to Deposit Account No. 03-2095.

Respectfully submitted,

Date: November 1, 1999

Susan M. Michaud
Paul T. Clark Susan M. Michaud
Reg. No. 30,162 Reg. No. 42,885

Clark & Elbing LLP
176 Federal Street
Boston, MA 02110
Telephone: 617-428-0200
Facsimile: 617-428-7045

\\Ceserver\documents\50019\50019.006001 preliminary amendment.wpd